{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:06:39Z","timestamp":1790100399181,"version":"4.0.1"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sub-Saharan Africa carries a disproportionate burden of HIV-associated malignancies. The contemporary tumour spectrum in the dolutegravir (DTG) era remains incompletely characterised in East African routine HIV-care settings. The immunovirological context at the time of cancer or benign tumor diagnosis is similarly under-described. We sought to describe the spectrum, malignant fraction, and immunovirological correlates of neoplasms diagnosed at a specialised HIV centre in Kampala, Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, cross-sectional analysis of 219 tumour records identified within the longitudinal clinical cohort of people living with HIV (PLHIV) in continuous care at Mildmay Hospital, contributed by 216 individual patients (three of whom each had two separate tumour diagnoses on different dates) between November 2017 and January 2026. Tumours were classified by ICD-10 disease group and malignancy status (benign\/malignant). Bivariate associations with malignancy status were tested using \u03c7\u00b2 or Fisher exact tests for categorical variables and Mann\u2013Whitney U tests for continuous variables (two-sided \u03b1\u2009=\u20090.05), with Benjamini\u2013Hochberg false discovery rate (FDR) correction applied across each panel of comparisons given the number of variables tested. Crude odds ratios (OR) with 95% confidence intervals (CI) were computed for dichotomous comparisons. A sensitivity analysis restricted to one tumour record per patient (n\u2009=\u2009216) was performed to assess the influence of the three patients with two records each.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort had a median age of 47 years (IQR 39\u201354) and was 127\/219 (58.0%) female. Overall, 138\/219 tumours (63.0%) were malignant. Kaposi sarcoma (KS) was the most frequently registered malignancy (n\u2009=\u200965; 47.1% of all malignant tumours; 29.7% of the full cohort). Among 155 records with viral load data, 133 (85.8%) were virally suppressed at tumour diagnosis, yet 70\/133 (52.6%) of those suppressed records were malignant. Advanced WHO clinical stage (III\/IV) at ART initiation was associated with malignant diagnosis (OR 3.51, 95% CI 1.54\u20138.81; FDR-adjusted p\u2009=\u20090.003). Median CD4 at ART initiation was lower among malignant compared with benign tumour records (147 vs 476 cells\/\u00b5L; FDR-adjusted p\u2009=\u20090.001), and median ART duration before diagnosis was shorter (37 vs 101 months; FDR-adjusted p\u2009&lt;\u20090.001). Restricting the analysis to KS versus other malignancies only (n\u2009=\u2009138), KS patients had lower CD4 at ART initiation (136 vs 171 cells\/\u00b5L, p\u2009=\u20090.079) and markedly shorter ART duration before diagnosis (4 vs 63 months, p\u2009&lt;\u20090.001) than patients with other malignancies. All associations were materially unchanged in the patient-level sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HIV-associated tumours in this Ugandan cohort remain predominantly malignant and are dominated by KS despite high viral suppression rates. Malignancy clusters among patients with low pre-ART CD4 counts, advanced WHO stage, and short ART duration, though these are unadjusted, hypothesis-generating comparisons rather than evidence of causal or temporal gradients. These data establish the analytic platform for a prospective HIV-oncology cohort at Mildmay Hospital and Mildmay Research Centre and inform context-appropriate cancer screening priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358066","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:30:42Z","timestamp":1790098242000},"page":"e0358066","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spectrum and immunovirological determinants of tumours among people living with HIV in Uganda: A retrospective cross sectional study from a specialised HIV centre, 2017\u20132026"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-0679","authenticated-orcid":true,"given":"Joseph","family":"Mwaka","sequence":"first","affiliation":[{"name":"Mildmay Research Centre","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Sserunjogi","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesca","family":"Natalayi","sequence":"additional","affiliation":[{"name":"Mildmay Research Centre","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"1","key":"pone.0358066.ref001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States","volume":"123","author":"EA Engels","year":"2008","journal-title":"Int J Cancer"},{"issue":"9581","key":"pone.0358066.ref002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"AE Grulich","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"pone.0358066.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/COH.0000000000000327","article-title":"Evolving epidemiology of HIV-associated malignancies","volume":"12","author":"MS Shiels","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"pone.0358066.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"RU Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"pone.0358066.ref005","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju503","article-title":"Excess cancers among HIV-infected people in the United States","volume":"107","author":"HA Robbins","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"pone.0358066.ref006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/COH.0000000000000025","article-title":"Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk","volume":"9","author":"AH Borges","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"pone.0358066.ref007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1750-9378-3-10","article-title":"Human herpesvirus-8 (HHV-8) sero-detection and HIV association in Kaposi\u2019s sarcoma (KS), non-KS tumors and non-neoplastic conditions","volume":"3","author":"AR Mwakigonja","year":"2008","journal-title":"Infect Agent Cancer"},{"key":"pone.0358066.ref008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-med-050409-103711","article-title":"The increasing burden of HIV-associated malignancies in resource-limited regions","volume":"62","author":"C Casper","year":"2011","journal-title":"Annu Rev Med"},{"issue":"2","key":"pone.0358066.ref009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/QAI.0b013e318251aedd","article-title":"A randomised controlled trial of HAART versus HAART and chemotherapy in therapy-na\u00efve HIV-associated Kaposi sarcoma in South Africa","volume":"60","author":"A Mosam","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pone.0358066.ref010","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1002\/ijc.28894","article-title":"Kaposi\u2019s Sarcoma in HIV-infected patients in South Africa: multicohort study in the antiretroviral therapy era","volume":"135","author":"J Bohlius","year":"2014","journal-title":"Int J Cancer"},{"issue":"7","key":"pone.0358066.ref011","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(08)70175-X","article-title":"Part I: cancer in indigenous africans--burden, distribution, and trends","volume":"9","author":"DM Parkin","year":"2008","journal-title":"Lancet Oncol"},{"key":"pone.0358066.ref012","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","DOI":"10.3322\/caac.21660"},{"issue":"3","key":"pone.0358066.ref013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056722","article-title":"Infection-related and lifestyle-related cancer burden in Kampala, Uganda: projection of the future cancer incidence up to 2030","volume":"12","author":"J Asasira","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0358066.ref014","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ijc.28661","article-title":"Trends in the incidence of cancer in Kampala, Uganda, 1991\u20132010","volume":"135","author":"HR Wabinga","year":"2014","journal-title":"Int J Cancer"},{"issue":"5","key":"pone.0358066.ref015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/QAI.0000000000001286","article-title":"Evaluation of a Predictive Staging Model for HIV-Associated Kaposi Sarcoma in Uganda","volume":"74","author":"F Okuku","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0358066.ref016","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ijc.33619","article-title":"Trends in childhood cancer incidence in sub-Saharan Africa: results from 25\u2009years of cancer registration in Harare (Zimbabwe) and Kyadondo (Uganda)","volume":"149","author":"O Stoeter","year":"2021","journal-title":"Int J Cancer"},{"key":"pone.0358066.ref017","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens. Geneva: WHO; 2019."},{"key":"pone.0358066.ref018","unstructured":"Uganda Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Kampala: MoH; 2020."},{"issue":"1","key":"pone.0358066.ref019","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1186\/s12879-021-06933-8","article-title":"Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study","volume":"21","author":"H Zakumumpa","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0358066.ref020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007690","article-title":"Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda","volume":"6","author":"AD Mwaka","year":"2016","journal-title":"BMJ Open"},{"issue":"10","key":"pone.0358066.ref021","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"EA Stewart","year":"2017","journal-title":"BJOG"},{"issue":"3","key":"pone.0358066.ref022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","article-title":"Epidemiology of clinical benign prostatic hyperplasia","volume":"4","author":"KB Lim","year":"2017","journal-title":"Asian J Urol"},{"issue":"3","key":"pone.0358066.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299904","article-title":"Integrated chronic care models for people with comorbid of HIV and non-communicable diseases in Sub-Saharan Africa: a scoping review","volume":"19","author":"R Chireshe","year":"2024","journal-title":"PLoS One"},{"key":"pone.0358066.ref024","article-title":"Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis","author":"P Patel","year":"2018","journal-title":"AIDS"},{"key":"pone.0358066.ref025","unstructured":"Uganda Ministry of Health. National HIV testing services policy and implementation guidelines. 4th ed. Kampala: MoH; 2022."},{"key":"pone.0358066.ref026","unstructured":"World Health Organization. International statistical classification of diseases and related health problems, 10th revision (ICD-10). Geneva: WHO; 2019."},{"issue":"20","key":"pone.0358066.ref027","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9596","key":"pone.0358066.ref028","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"pone.0358066.ref029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/infdis\/jix569","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus in a rural Ugandan cohort, 1992\u20132008","volume":"217","author":"R Newton","year":"2018","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0358066.ref030","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0b013e31828a7056","article-title":"Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda","volume":"63","author":"K Wakeham","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"pone.0358066.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008681","article-title":"Comparative transcriptome analysis of endemic and epidemic Kaposi\u2019s sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis","volume":"16","author":"SJ Lidenge","year":"2020","journal-title":"PLoS Pathog"},{"issue":"6","key":"pone.0358066.ref032","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus inflammatory cytokine syndrome","volume":"62","author":"MN Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0358066.ref033","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.7448\/IAS.19.1.20697","article-title":"Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era","volume":"19","author":"W Cao","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0358066.ref034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/M16-2094","article-title":"Association of Viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study","volume":"169","author":"LS Park","year":"2018","journal-title":"Ann Intern Med"},{"issue":"14","key":"pone.0358066.ref035","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/QAD.0000000000000382","article-title":"Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009","volume":"28","author":"M Hleyhel","year":"2014","journal-title":"AIDS"},{"issue":"4","key":"pone.0358066.ref036","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"SG Deeks","year":"2013","journal-title":"Immunity"},{"issue":"12","key":"pone.0358066.ref037","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1055-9965.EPI-11-0777","article-title":"HIV infection, immunodeficiency, viral replication, and the risk of cancer","volume":"20","author":"MJ Silverberg","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"pone.0358066.ref038","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cit369","article-title":"Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy","volume":"57","author":"EL Yanik","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0358066.ref039","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cid\/cir802","article-title":"Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy","volume":"54","author":"CJ Achenbach","year":"2012","journal-title":"Clin Infect Dis"},{"key":"pone.0358066.ref040","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020."}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:30:50Z","timestamp":1790098250000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358066"}},"subtitle":[],"editor":[{"given":"Felix","family":"Bongomin","sequence":"first","affiliation":[{"name":"Gulu University","place":["UGANDA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358066","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}